SELLAS Life Sciences Group, Inc. (SLS) DCF Valuation

SELLAS Life Sciences Group, Inc. (SLS) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

SELLAS Life Sciences Group, Inc. (SLS) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our SELLAS Life Sciences Group, Inc. (SLS) DCF Calculator enables you to evaluate the valuation of SELLAS Life Sciences Group, Inc. with real-world financial data and complete flexibility to modify all essential parameters for improved projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 1.9 7.6 1.0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 300 -86.84 -100 -21.71 -21.71 -21.71 -21.71 -21.71
EBITDA .7 -16.4 -19.7 -32.0 .5 .0 .0 .0 .0 .0
EBITDA, % 100 -863 -258.72 -3195 100 -20 -20 -20 -20 -20
Depreciation 17.2 .4 1.3 .5 37.9 .0 .0 .0 .0 .0
Depreciation, % 100 19.84 16.75 45.7 100 56.46 56.46 56.46 56.46 56.46
EBIT -16.5 -16.8 -20.9 -32.4 -37.3 .0 .0 .0 .0 .0
EBIT, % 100 -882.84 -275.47 -3240.7 100 -20 -20 -20 -20 -20
Total Cash 7.3 35.3 21.4 17.1 2.5 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .3 .0 .0 .0 .0
Account Receivables, % 100 0 0 0 100
Inventories .6 .5 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 24.47 0 0 100 44.89 44.89 44.89 44.89 44.89
Accounts Payable 3.9 4.7 2.1 3.4 5.6 .0 .0 .0 .0 .0
Accounts Payable, % 100 245.11 28.21 335.7 100 85.64 85.64 85.64 85.64 85.64
Capital Expenditure .0 .0 .0 -4.5 -5.5 .0 .0 .0 .0 .0
Capital Expenditure, % 100 0 0 -450 100 -20 -20 -20 -20 -20
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -16.5 -16.8 -20.7 -31.9 -37.3 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF 3.8 -15.2 -21.5 -34.7 -2.7 -5.6 .0 .0 .0 .0
WACC, % 15.39 15.39 15.39 15.39 15.39 15.39 15.39 15.39 15.39 15.39
PV UFCF
SUM PV UFCF -4.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -5
Net Debt -2
Equity Value -3
Diluted Shares Outstanding, MM 28
Equity Value Per Share -0.12

What You Will Get

  • Editable Forecast Inputs: Easily modify assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: SELLAS Life Sciences Group, Inc. (SLS) financial data pre-filled to enhance your analysis.
  • Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
  • Customizable and Professional: A refined Excel model tailored to meet your valuation requirements.
  • Built for Analysts and Investors: Perfect for testing projections, validating strategies, and optimizing time efficiency.

Key Features

  • Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for SELLAS Life Sciences Group, Inc. (SLS).
  • WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
  • Customizable Forecast Assumptions: Adjust growth projections, capital investments, and discount rates as needed.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to SELLAS Life Sciences Group, Inc. (SLS).
  • Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered SELLAS Life Sciences Group, Inc. (SLS) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for SELLAS Life Sciences Group, Inc. (SLS) intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose SELLAS Life Sciences Group, Inc. (SLS)?

  • Innovative Solutions: Benefit from cutting-edge therapies designed to meet unmet medical needs.
  • Proven Expertise: Our team comprises industry veterans with extensive experience in drug development.
  • Robust Pipeline: A diverse portfolio of candidates targeting various cancers and autoimmune diseases.
  • Commitment to Quality: Stringent processes ensure the highest standards in research and development.
  • Partnership Opportunities: Collaborate with us to leverage our scientific advancements for mutual growth.

Who Should Use SELLAS Life Sciences Group, Inc. (SLS)?

  • Investors: Gain insights into innovative therapies and make informed investment choices.
  • Healthcare Analysts: Utilize comprehensive data to evaluate the potential of groundbreaking treatments.
  • Consultants: Tailor reports and presentations with the latest research on SLS's product pipeline.
  • Pharmaceutical Enthusiasts: Enhance your knowledge of the biotech industry through in-depth analysis of SLS’s advancements.
  • Educators and Students: Leverage real-world case studies in biopharmaceuticals for educational purposes.

What the Template Contains

  • Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for SELLAS Life Sciences Group, Inc. (SLS).
  • Real-World Data: SELLAS Life Sciences’ historical and projected financials preloaded for analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to test various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for deeper insights into SELLAS Life Sciences Group, Inc. (SLS).
  • Key Ratios: Built-in analysis for profitability, efficiency, and leverage specific to SELLAS Life Sciences Group, Inc. (SLS).
  • Dashboard with Visual Outputs: Charts and tables for clear, actionable results related to SELLAS Life Sciences Group, Inc. (SLS).

No products were found matching.